Iruplinalkib
- Generic Name
- Iruplinalkib
- Drug Type
- Small Molecule
- CAS Number
- 1854943-32-0
- Unique Ingredient Identifier
- Z5F65W1YAZ
- Indication
用于既往接受过克唑替尼治疗后疾病进展或对克唑替尼不耐受的间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的治疗。
An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06436885
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial
Phase 2
Not yet recruiting
- Conditions
- Potentially Resectable ALK Positive Non-Small Cell Lung Cancer
- Interventions
- Procedure: surgery
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 20
- Registration Number
- NCT06282536
Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer
Recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Jinming Yu
- Target Recruit Count
- 5000
- Registration Number
- NCT05991895
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05801107
- Locations
- 🇨🇳
Shanghai Jiao Tong University Chest Hospital, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath